Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 16/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583919 | 0.95 | MPO (0.72) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL31620029 | 0.89 | MPO (0.71) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL733767 | 0.89 | MPO (0.71) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL5203031 | 0.84 | MPO (0.73) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL3705476 | 0.84 | MPO (1.00) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL7846163 | 0.84 | MPO (0.77) | MPOSLC6A4HTR2ATRPM8 | |
| SCHEMBL4637101 | 0.84 | MPO (0.73) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL6972588 | 0.83 | MPO (1.00) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL2403830 | 0.83 | MPO (1.00) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL7819881 | 0.83 | MPO (1.00) | MPOSLC6A4HTR2ATRPM8HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103977004-B | The medicinal usage of indole piperazine derivative | 复旦大学 | 2016-08-10 | — | — | CN | disclosed |
| CN-100384849-C | Quinoline 3-Aminochroman Derivatives | WYETH CORP (US) | 2008-04-30 | — | — | CN | disclosed |
| US-20070191417-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | HATZENBUHLER NICOLE T | 2007-08-16 | — | — | US | disclosed |
| US-7227023-B2 | Quinoline 3-amino chroman derivatives | WYETH (US) | 2007-06-05 | — | — | US | disclosed |
| CN-1809574-A | Quinoline 3-amino chroman derivatives | WYETH CORP (US) | 2006-07-26 | — | — | CN | disclosed |
| EP-1638976-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | Wyeth (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050004157-A1 | Quinoline 3-amino chroman derivatives | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099214-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191417-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | HTR3C, HTR3A, HTR2C | MPO 2871/4885SLC6A4 27/4885HTR2A 7/4885 |
| US-20050004157-A1 | Quinoline 3-amino chroman derivatives | HTR3C, HTR3A, HTR2C | MPO 2871/4885SLC6A4 27/4885HTR2A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.